Zaki, Bishoy MaherHussein, Assmaa HHakim, Toka AFayez, Mohamed SEl-Shibiny, Ayman2023-04-302023-04-302023-04https://doi.org/10.1016/bs.pmbts.2023.03.007http://repository.msa.edu.eg/xmlui/handle/123456789/5564Abstract Klebsiella pneumoniae is an opportunistic pathogen involved in both hospital- and community-acquired infections. K. pneumoniae is associated with various infections, including pneumonia, septicemia, meningitis, urinary tract infection, and surgical wound infection. K. pneumoniae possesses serious virulence, biofilm formation ability, and severe resistance to many antibiotics especially hospital-acquired strains, due to excessive use in healthcare systems. This limits the available effective antibiotics that can be used for patients suffering from K. pneumoniae infections; therefore, alternative treatments are urgently needed. Bacteriophages (for short, phages) are prokaryotic viruses capable of infecting, replicating, and then lysing (lytic phages) the bacterial host. Phage therapy exhibited great potential for treating multidrug-resistant bacterial infections comprising K. pneumoniae. Hence, this chapter emphasizes and summarizes the research articles in the PubMed database from 1948 until the 15th of December 2022, addressing phage therapy against K. pneumoniae. The chapter provides an overview of K. pneumoniae phages covering different aspects, including phage isolation, different morphotypes of isolated phages, in vitro characterization, anti-biofilm activity, various therapeutic forms, in vivo research and clinical studies.en-USKlebsiella pneumoniaeMultidrug-resistancePhage therapyPhage cocktailAntibiofilmAntibacterialIn vivo studyClinical studyPhages for treatment of Klebsiella pneumoniae infections Author links open overlay panelArticlehttps://doi.org/10.1016/bs.pmbts.2023.03.007